|
See related Noxafil oral susp information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Zuellig |
|
Contents |
Posaconazole |
|
Indications |
Treatment of oropharyngeal candidiasis, invasive aspergillosis, esophageal candidiasis or candidemia, fusariosis, zygomycosis, cryptococcosis, chromoblastomycosis, mycetoma. Prophylaxis of invasive fungal infections including yeasts & moulds in high-risk patients (eg, patients w/ prolonged neutropenia or hematopoietic stem cell transplant recipients).
Click to view Noxafil detailed prescribing infomation |
|
Dosage |
Patient ≥13 yr Refractory invasive fungal infections (IFI)/intolerant patients w/ IFI 10 mL bid or 5 mL 4 times a day. Oropharyngeal candidiasis 5 mL once a day on the 1st day then 2.5 mL once a day for 13 days. Refractory oropharyngeal or oesophageal candidiasis 10 mL bid. Prophylaxis of IFI 5 mL tid.
Click to view Noxafil detailed prescribing infomation |
|
Overdosage |
View Noxafil overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken with food (Take w/ a full meal or w/ 240 mL of liqd nutritional supplement in patients who cannot eat a full meal.). |
|
Contraindications |
Concomitant ergot alkaloids, CYP3A4 substrates (terfenadine, astemizole, cisapride, pimozide, halofantrine, quinidine), HMG-CoA reductase inhibitors (simvastatin, lovastatin, atorvastatin).
Click to view Noxafil detailed prescribing infomation |
|
Special Precautions |
Hypersensitivity to other azoles. Hepatic toxicity (monitor hepatic function). Congenital or acquired QTc prolongation, cardiomyopathy, sinus bradycardia, existing symptomatic arrhythmias. Monitor K, Mg, Ca levels. Glucose-galactose malabsorption. Pregnancy, lactation.
Click to view Noxafil detailed prescribing infomation |
|
Adverse Drug Reactions |
Neutropenia; electrolyte imbalance, anorexia; paresthesia, dizziness, somnolence, headache; GI disorders; elevated liver function tests; rash; asthenia, fatigue, pyrexia.
View ADR Monitoring Form |
|
Drug Interactions |
Drugs that prolong QTc interval, diltiazem, verapamil, nifedipine, nisoldipine. Decreased conc w/ rifabutin, rifampicin, phenytoin, carbamazepine, phenobarb, primidone, cimetidine, efavirenz. P-glycoprotein inhibitors or inducers may increase or decrease posaconazole conc. Increase conc of midazolam, ergot alkaloids, vinca alkaloids, cyclosporine, tacrolimus, sirolimus; HIV protease and non-nucleoside reverse transcriptase inhibitors; digoxin. Glucose conc decreased when co-administered w/ glipizide.
View more drug interactions with Noxafil |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Noxafil storage conditions for details to ensure optimal shelf-life. |
|
Mechanism of Action |
View Noxafil mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
